Laga Silaturrahim Tour dE Jogja, Ikatek FC Akui Kolektifitas Kagama FC

World

Sleman, Yogyakarta – Tour dE Jogja tim sepakbola Ikatan Alumni Fakultas Teknik Universitas Hasanuddin, Ikatek FC melawan Keluarga Alumni Gadjah Mada (Kagama FC) di Lapangan Pakembinangun, Sleman. Ahad, 21/5/2023. Laga yang bertajuk “Football Fun Games” yang merupakan ajang silaturrahim ini berlangsung selama 4 babak. Pada babak pertama, Ikatek FC tertinggal 1 gol namun pada babak […]

Terkini

Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis LONDON, UK - EQS Newswire - 10 June 2022 - Financial information from over 100 multinational drug companies, involving over 70,000 data points, have been accumulated over the past 35 years to create a pharmaceutical database. All our data (sales, COGS, SG&A, R&D and other income) have been derived from annual reports, regulatory filings and company presentations, and then analysed, wherever possible, in a like-for-like manner, irrespective of how each company presents the data. This is a key differentiator to competitive products and is important because all company management teams report "adjusted", "core", or "non-GAAP" earnings to show themselves in the best possible light. However, different inclusion/exclusion criteria in the generation of these adjustments lead to distortions and variability. Although some of the companies are multi-divisional, another key differentiator is the extraction and analysis of data for the pharmaceutical segment only. This product is unique because it analyses the individual cost components of each company over time and generates pharma industry weighted averages, allowing peer and industry comparisons to be made. It also generates individual company and industry-wide underlying operating profit (EBIT), both pre-R&D and post R&D. Historically, data from over 100 companies has been accumulated, but industry consolidation means that just 40 are included currently, which command an estimated 76% of the global drug industry. The main exceptions are the Chinese companies where insufficient data are available on a consistent basis. Current companies included in dataset: Click here to find out more: https://hardmanandco.com/2021-pharma-statistics-long-term-cost-underlying-ebit-analysis/ Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.

Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis

World

Betterment moves beyond robo-advising with human financial planners

Food

Magical fish basically has the power to conjure its own Patronus

Food

Oil spill off India’s southern coast leaves fisherman stranded, marine life impacted

Movie

You can now play Bill Gates’ first PC game and run over donkeys on your iPhone, Apple Watch

Apps

How Nike plans to break one of the most daunting barriers in human performance

Fashion

The Chainsmokers Actually Make a Great Nickelback Cover Band

Health

J.K. Rowling Is Shutting Down Readers Who Burned All Their Harry Potter Books

Fashion

The Scary Reason Healthy People Die After an ER Visit

Gaming

Watch Justin Timberlake’s ‘Cry Me a River’ Come to Life in Mesmerizing Dance

Business

Barack Obama’s Now Mainly Focusing on Wearing This Casual Backwards Hat

Movie

Lady Gaga Pulled Off One of the Best Halftime Shows Ever

Movie
Sudah ditampilkan semua
Tutup